Adenovirus (Ad)-mediated gene delivery is a promising approach for genetic manipulation of the vasculature and is being used in both preclinical models and clinical trials. However, safety concerns relating to infection of nontarget tissue and the poor infectivity of vascular cells compared to other cell types necessitates Ad vector refinement. Here, we combine a transductional targeting approach to improve vascular cell infectivity through RGD peptide insertion into adenovirus fibers, combined with transcriptional targeting to endothelial cells using a E1 kb fragment of the fms-like tyrosine kinase receptor-1 (FLT-1) promoter. Single-and double-modified vectors were characterized in human cell lines that either support or have silenced FLT-1 expression.
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Adenovirus (Ad)-mediated gene delivery is a promising approach for genetic manipulation of the vasculature and is being used in both preclinical models and clinical trials. However, safety concerns relating to infection of nontarget tissue and the poor infectivity of vascular cells compared to other cell types necessitates Ad vector refinement. Here, we combine a transductional targeting approach to improve vascular cell infectivity through RGD peptide insertion into adenovirus fibers, combined with transcriptional targeting to endothelial cells using a E1 kb fragment of the fms-like tyrosine kinase receptor-1 (FLT-1) promoter. Single-and double-modified vectors were characterized in human cell lines that either support or have silenced FLT-1 expression.
In rat hepatocytes and endothelial cells, the double modification substantially shifted transduction profiles toward vascular endothelial cells. Furthermore, in intact aortae derived from spontaneously hypertensive rats that display enhanced av integrin expression on dysfunctional endothelium, enhanced levels of transduction were observed using the double-modified vector but not in aortae derived from normotensive control rats. Our data indicate that Admediated transduction can be beneficially modified in vitro and in vivo by combining fiber modification and a cellselective promoter within a single-component vector system. ). Previous studies, using both adenoviruses (Ad) 6, 7 and adeno-associated viruses (AAV), 8 have demonstrated the ability of the cyclic RGD-4C peptide 9 to retarget vector tropism through av integrins, leading to enhanced gene delivery to a repertoire of cell types. This is particularly important for cell types that have low or negligible coxsackie and adenovirus receptor (CAR) or heparan sulfate proteoglycans (HSPG) expression, the primary receptors for Ad 5 and AAV-2, respectively. [10] [11] [12] It is important to note, however, that vectors modified in this manner are not selective and can transduce a wide repertoire of cell types. In fact, RGD-modified vectors were originally developed to broaden the tropism of Adbased vectors. 6, 7 Strategies to maintain the increased transduction afforded by RGD modification but on a cellselective basis would increase the utility and safety of this system. Of particular importance in this regard is the widespread use of cytotoxic and cytostatic strategies in cancer and cardiovascular gene therapy applications. Maintaining cell selectivity in this context is critically important. Even for local gene delivery to arteries in vivo, Ad dissemination has been shown to occur in abundance, leading to transgene expression in distant tissues, including the liver. 13 Cell-selective promoters provide an opportunity to develop such vectors within singlecomponent systems. This has been demonstrated in the context of cancer cells in vitro using the RGD-4C motif and cyclo-oxygenase-2 promoter.
14 The fms-like tyrosine kinase receptor-1 (FLT-1) promoter is highly active in human endothelial cells in vitro, in human vessels ex vivo, 15 in pulmonary vasculature in vivo 16 and in certain cancer cells lines. 17, 18 It is therefore a very powerful promoter for driving selectivity for a variety of gene therapy applications in cardiovascular disease and cancer.
We therefore constructed a panel of vectors expressing the luciferase reporter gene from either the cytomegalovirus (CMV) immediate-early promoter or the endothelial cell-selective FLT-1 promoter in combination with either nonmodified Ad 5 capsids or with the RGD-4C peptide genetically inserted into the HI loop. To characterize the transductional and transcriptional targeting of each vector, we used three human cell lines that are either permissive (HeLa, PC3) or poorly infected (HT29) by Ad 5 vectors (Figure 1 ). In addition, PC3 and HT29 cells but not HeLa cells support FLT-1 transcription. 18 This allowed the evaluation of both the RGD and FLT-1 targeting components for each vector (Figure 1 ).
We used short (30 and 60 min) and longer (18 h) time points for virus:cell exposure, as previous studies have highlighted the improved uptake by RGD-modified vectors. 6, 8 Quantification of transgene expression in Figure 1 Transduction of human cell lines by RGD-and FLT-1-modified Ad vectors. Four recombinant adenoviruses were used: AdCMV.luc (containing the CMV promoter and nonmodified fiber), AdCMV.RGDluc (CMV promoter with an RGD insert into fiber), AdFLT-1.luc (FLT-1 promoter with nonmodified fiber) and AdRGD.FLT-1luc (combination of FLT-1 promoter and RGD insertion). AdFLT-1.luc and AdRGD.FLT-1luc were constructed by homologous recombination between FLT-1 16 and RGD.FLT-1 plasmids with a modified version of pTG3602 containing the RGD insert in the HI loop. 6 Infectious and particle titers were determined for each preparation of virus used as described. 26, 27 Cells were plated into 96-well plates at 3 Â 10 4 cells/well 24 h prior to infection. Cells were then incubated with virus for 10 min, 30 min or overnight. The cells were washed twice in phosphate-buffered saline (PBS) and the media changed. After 24 h, the cells were again washed in PBS and lysed using reporter lysis buffer (RLB). Cell lysates or homogenate suspensions were quantified for firefly luciferase activity using the Luciferase Assay System (Promega). The 96-well plates were prepared using 5 ml/well of lysate or 10 ml/well of homogenate suspension diluted to a total volume of 100 ml with RLB. A measure of 100 ml of Luciferase Assay Reagent was added to each well and the plate immediately read for 10 s/well. Detection was achieved using a Wallac 1420 (VICTOR2) Multilabel Counter with recombinant luciferase as a standard. Reporter gene expression was normalized for total protein using a BCA protein assay (Perbio, UK) with bovine serum albumin (Sigma, UK) standard and measured using a VICTOR2 plate reader. We next analyzed the capacity of each virus to transduce rat endothelial cells and hepatocytes. The rat is an important model system for the development of cardiovascular gene therapy, for example, endothelial cell dysfunction associated with hypertension, left ventricular hypertrophy and stroke. [19] [20] [21] Importantly, transduction of rat arteries is relatively poor using nonmodified vectors and high titers are required. [22] [23] [24] We compared transduction evoked by AdCMV.luc with AdFLT-1.luc (Figure 2a) . In ARL-6 hepatocytes, transduction driven by AdFLT.luc was substantially reduced compared to AdCMV.luc. RGD modification failed to increase transduction of ARL-6 cells compared to AdCMV.luc (not shown) and AdFLT-1.luc and AdFLT-1.RGD.luc evoked lower levels compared to AdCMV.luc (Figure 2a) . Transduction of RGE endothelial cells was noticeably different. FLT-1 transcription was active since expression by AdFLT-1.luc was comparable to AdCMV.luc (Figure 2a) . However, AdRGD.FLT-1luc Figure 3 Gene delivery to intact rat aortae ex vivo. Aortae were excised from WKY and SHRSP under terminal anesthesia in accordance with the Animals (Scientific Procedures) Act, 1986. Vessels were cleaned of surrounding connective and fatty tissues and cut into segments. During preparation, vessels were maintained in wash medium (RPMI supplemented with 100 IU/ml penicillin, 100 mg/ml streptomycin and 2 mmol/l L-glutamine). Aortic segments were then incubated with Ad vectors for 10, 30 or 60 min before being washed twice in PBS. Segments were maintained during and after infection in wash medium supplemented with 30% (v/v) foetal calf serum (FCS) and incubated for 5 days. At the end of the incubation period, the aortic segments were snap frozen in liquid nitrogen and homogenized in liquid N 2 using a mortar and pestle. Homogenate was suspended in 100 ml RLB and kept on ice for 1 h, then supernatants analyzed for luciferase expression. *Po0.05 vs AdFLT-1.luc at same exposure time, n ¼ 4 animals/time point. 
Dual targeting of adenovirus vectors
LM Work et al resulted in a significant increase in transduction ( Figure  2a ). These opposing effects in hepatocytes and endothelial cells resulted in a marked shift in tropism. Compared to AdCMV.luc, the double-targeted AdRGD.FLT-1luc vector resulted in a substantial increase in the ratio of infectivity for endothelial cells compared to hepatocytes (Figure 2b) . Based on this, we transduced intact rat aortae with either AdFLT-1luc or AdRGD.FLT-1luc. We used aortae from both normotensive Wistar Kyoto (WKY) animals and those from stroke-prone spontaneously hypertensive (SHRSP) rats. Previous studies have shown that av integrin levels are enhanced on the dysfunctional endothelium in spontaneously hypertensive rats, but not in controls. 25 This therefore allowed the evaluation of FLT-1 activity and RGD targeting with a single vector system in a disease model. We used short exposure times of virus:vessel (30 and 60 min), since this is a limitation for vascular gene delivery. Comparison of transgene levels in WKY aortae exposed to AdFLT-1.luc or AdFLT-1.RGDluc showed no further enhancement in reporter gene levels, on RGD incorporation (Figure 3) . In comparison, a significant increase in transduction was selectively observed in SHRSP aorta exposed to AdRGD.FLT-1luc compared to AdFLT-1.luc with an approximate seven-fold increase in transduction levels ( Figure 3 ). In addition, to assess whether the double-modified vector showed reduced transgene expression in the liver following systemic administration, we injected AdCMV.luc or AdFLT-1.RGDluc into 12-week-old SHRSP animals. The double-modified vectors showed substantially reduced liver transgene levels measured 5 days postinjection (Figure 4) , further demonstrating the potential safety benefit of the double targeting approach in vivo. This underscores the potential utility of this approach to afford high-level, selective gene delivery to defined cells and tissues and provides the first experimental evidence in vitro and in vivo that this can be achieved in a singlecomponent system. While we have focused on Ad vectors in this study, equivalent modifications are likely to be beneficial for a broad range of gene delivery vector systems. Taken together, the development of singlecomponent, dual-targeted viruses through peptide insertion in the HI loop of Ad fibers and transcriptional control by cell-selective promoters is an important mechanism though which to improve the selectivity and efficiency of gene delivery to defined cell types.
